Skip to main content

Table 1 Urine output, free water clearance (CH2O), urinary AQP2 excretion per minute (u-AQP2), urinary sodium excretion (u-Na), and urinary potassium excretion (u-K) during 24-h urine collection in a randomised, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

 

Before each examination day

p (paired t-test)

Placebo

Tolvaptan 60 mg

Urine Output (ml/24 h)

2504 ± 518

2446 ± 615

0.57

CH2O (ml/min)

−0.22 ± 0.55

−0.19 ± 0.57

0.72

u-AQP2 (ng/min)

1.10 ± 0.26

1.09 ± 0.28

0.88

u-Na (mmol/24 h)

117 ± 34

111 ± 28

0.46

u-K (mmol/24 h)

66 ± 17

65 ± 18

0.77

  1. Values are means with ± SD. Paired t-test was used for comparison between groups
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us